JP2023528039A5 - - Google Patents
Info
- Publication number
- JP2023528039A5 JP2023528039A5 JP2022573508A JP2022573508A JP2023528039A5 JP 2023528039 A5 JP2023528039 A5 JP 2023528039A5 JP 2022573508 A JP2022573508 A JP 2022573508A JP 2022573508 A JP2022573508 A JP 2022573508A JP 2023528039 A5 JP2023528039 A5 JP 2023528039A5
- Authority
- JP
- Japan
- Prior art keywords
- target rna
- modified
- domain
- polynucleotide
- polynucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029996P | 2020-05-26 | 2020-05-26 | |
| US63/029,996 | 2020-05-26 | ||
| US202063112488P | 2020-11-11 | 2020-11-11 | |
| US63/112,488 | 2020-11-11 | ||
| US202063119902P | 2020-12-01 | 2020-12-01 | |
| US63/119,902 | 2020-12-01 | ||
| US202163178056P | 2021-04-22 | 2021-04-22 | |
| US63/178,056 | 2021-04-22 | ||
| PCT/US2021/034301 WO2021242889A1 (en) | 2020-05-26 | 2021-05-26 | Engineered circular polynucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528039A JP2023528039A (ja) | 2023-07-03 |
| JP2023528039A5 true JP2023528039A5 (enExample) | 2024-05-09 |
Family
ID=76523478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573508A Pending JP2023528039A (ja) | 2020-05-26 | 2021-05-26 | 改変環状ポリヌクレオチド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230174977A1 (enExample) |
| EP (1) | EP4158017A1 (enExample) |
| JP (1) | JP2023528039A (enExample) |
| WO (1) | WO2021242889A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| CA3035293A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| CN114269919B (zh) * | 2019-07-12 | 2023-08-18 | 北京大学 | 采用工程化rna利用内源adar进行靶向的rna编辑 |
| AU2020395113A1 (en) | 2019-12-02 | 2022-06-09 | Shape Therapeutics Inc. | Therapeutic editing |
| US20230036370A1 (en) * | 2019-12-02 | 2023-02-02 | The Regents Of The University Of California | Engineering circular guide rnas |
| WO2022150974A1 (en) * | 2021-01-12 | 2022-07-21 | Peking University | Targeted rna editing by leveraging endogenous adar using engineered rnas |
| US20250154504A1 (en) | 2022-02-14 | 2025-05-15 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| CN120322556A (zh) | 2022-12-09 | 2025-07-15 | ProQR治疗上市公司Ⅱ | 用于治疗心血管疾病的反义寡核苷酸 |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| JP2026510408A (ja) | 2023-03-24 | 2026-04-02 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 神経障害の処置のためのアンチセンスオリゴヌクレオチド |
| CN121002181A (zh) | 2023-03-27 | 2025-11-21 | ProQR治疗上市公司Ⅱ | 用于治疗肝脏疾病的反义寡核苷酸 |
| WO2024235293A1 (zh) * | 2023-05-17 | 2024-11-21 | 中国科学院遗传与发育生物学研究所 | 基于环状rna的引导编辑系统 |
| AR132964A1 (es) | 2023-06-16 | 2025-08-13 | Proqr Therapeutics Ii Bv | Oligonucleótidos antisentido para el tratamiento de enfermedades neurodegenerativas |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| AU2024379264A1 (en) | 2023-11-16 | 2026-05-14 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025137637A2 (en) * | 2023-12-21 | 2025-06-26 | Shape Therapeutics Inc. | Wobble base pairs for improving specificity of rna editing |
| WO2025207635A1 (en) * | 2024-03-25 | 2025-10-02 | University Of Wyoming | Compositions and methods for stabilizing a biological material or biologically-derived material |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026093339A1 (en) | 2024-10-29 | 2026-05-07 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2925866B1 (en) * | 2012-11-30 | 2018-07-25 | Aarhus Universitet | Circular rna for inhibition of microrna |
| ES2810375T3 (es) * | 2014-12-17 | 2021-03-08 | Proqr Therapeutics Ii Bv | Edición direccionada de ARN |
| EP3475424A1 (en) * | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018237372A1 (en) * | 2017-06-23 | 2018-12-27 | Cornell University | RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT |
| US20220010333A1 (en) * | 2018-09-06 | 2022-01-13 | The Regents Of The University Of California | Rna and dna base editing via engineered adar recruitment |
| CN114269919B (zh) * | 2019-07-12 | 2023-08-18 | 北京大学 | 采用工程化rna利用内源adar进行靶向的rna编辑 |
| US20230036370A1 (en) * | 2019-12-02 | 2023-02-02 | The Regents Of The University Of California | Engineering circular guide rnas |
-
2021
- 2021-05-26 JP JP2022573508A patent/JP2023528039A/ja active Pending
- 2021-05-26 WO PCT/US2021/034301 patent/WO2021242889A1/en not_active Ceased
- 2021-05-26 EP EP21733641.1A patent/EP4158017A1/en not_active Withdrawn
- 2021-05-26 US US17/998,322 patent/US20230174977A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qiao et al. | Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver | |
| CN109072235B (zh) | 通过核递送crispr/cas9追踪并操纵细胞rna | |
| JP2023527354A5 (enExample) | ||
| EP3129485B1 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| AU2017379073B2 (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| US20060234247A1 (en) | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing | |
| Moshiri et al. | Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma | |
| JP2021511047A5 (enExample) | ||
| CN101460624B (zh) | 具有iNOS的表达控制作用的正义寡核苷酸以及含有其的组合物 | |
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| WO2023165009A1 (zh) | 一种用于制备环状rna的载体及其应用 | |
| JP2022505381A5 (enExample) | ||
| JP2005501557A5 (enExample) | ||
| IL292999A (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| Valdmanis et al. | RNA interference–induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice | |
| BR112016023004B1 (pt) | Sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma | |
| WO2019196887A1 (zh) | 一种新型小激活rna | |
| JP2024504608A (ja) | 遺伝子操作ｒｎａを使用した内因性ａｄａｒの活用による標的化ｒｎａの編集 | |
| JP2024543782A (ja) | Ｃａｇリピート疾患を治療するための組成物および方法 | |
| Mendoza et al. | Structural and functional effects of inosine modification in mRNA | |
| JP2021511035A5 (enExample) | ||
| JP2022534627A (ja) | Ｄｍｐｋ遺伝子を標的とした筋ジストロフィーの治療方法 | |
| Garcia-Guerra et al. | Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs | |
| CN113584027B (zh) | 一种激活p21基因表达的方法 | |
| JP2022522166A5 (enExample) |